Total Value in 2011: $13,545.95M* Number of Deals in 2011: 143 | ||||
Company (Location) |
Company (Location) |
Value (M) |
Type/Product Area |
Terms/Details (Date) |
JUNE | ||||
Affectis Pharmaceuticals AG (Munich, Germany) |
Merck Serono (division of Merck KgaA; Darmstadt, Germany) |
$407.5 |
Deal to develop neurology compounds targeting P2X7 receptors, a calcium channel thought to play a role in neuroprotection |
The deal gives Merck worldwide rights to develop and commercialize the compounds in exchange for $3.5M up front, plus research funding, with a potential $404M in milestones, plus royalties (6/9) |
Audion Therapeutics (Amsterdam, the Netherlands) |
Sanofi-Aventis SA (Paris) |
ND |
Two-year research collaboration to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach |
Sanofi has an option to license technology rights from Audion (6/17) |
AVEO Pharmaceuticals Inc. (Cambridge, Mass.) |
Centocor Ortho Biotech Inc. (Horsham, Pa.; unit of Johnson & Johnson) |
$555 |
Exclusive worldwide development and commercialization deal to AVEO's preclinical antibodies targeting the RON receptor |
Centocor paid $15M up front, and will pay as much as $540M in milestones, plus double-digit royalties on worldwide net sales (6/1) |
BioMarin Pharmaceutical Inc. (Novato, Calif.) |
Pfizer Inc. (New York) |
$48.5 |
Purchase of a bulk biologics manufacturing plant in Cork, Ireland from Pfizer |
BioMarin paid $48.5M for the plant, which will produce enzyme replacement therapy GALNS, as well as other products (6/24) |
BioPontis Alliance LLC (Raleigh, N.C.) |
Janssen Biotech Inc. (Horsham, Pa.; formerly Centocor Ortho Biotech Inc.; part of Johnson & Johnson) |
ND |
Translational Research Agreement for drug development |
BioPontis will receive input and guidance to ensure its early programs are aligned with market demand; Janssen will have access to evaluate and license early stage therapeutic opportunities (6/30) |
Biotest AG ( Dreieich, Germany) |
Abbott (Abbott Park, Ill.) |
$480 |
Autoimmune disease deal focused on BT-061 for rheumatoid arthritis and psoriasis |
Biotest gets $85M up front and is eligible for $395M in milestones, plus royalties on worldwide sales, except in Europe, where the companies will co-promote BT-061 (6/22) |
Clovis Oncology Inc. (Boulder, Colo.) |
Pfizer Inc. (New York) |
$255 |
Deal for the right to develop and commercialize PF-01367338, an inhibitor of Poly ADP-ribose polymerase inhibitor, which is in Phase I/II development for solid tumors |
Clovis will pay an undisclosed up-front fee to Pfizer, plus potential milestones of $255M; Pfizer Venture Investments will make an equity investment in Clovis (6/6) |
Clovis Oncology Inc. (Boulder, Colo.) |
Roche AG (Basel, Switzerland) |
ND |
Partnership to develop a PCR-based companion diagnostic test for epidermal growth factor receptor mutations in non-small-cell lung cancer |
The test is being developed to support CO-1686, which targets the T790M mutant form of EGFR (6/3) |
Cortex Pharmaceuticals Inc. (Irvine, Calif.) |
Servier (Paris) |
$1 |
Agreement to sell rights to CX1632 to Servier for an up-front payment of $1M |
The companies will remain joint owners of related patents; in the event that Servier opts to acquire sole ownership of patent rights to CX1632, it will pay Cortex an additional $2M (6/14) |
Evotec AG (Hamburg, Germany) |
Roche AG (Basel, Switzerland) |
ND |
Collaboration to identify appropriate pharmacodynamics and protein-activity-based patient stratification biomarkers for Roche's oncology drugs |
Evotec will use its phosphoScout platform to discover protein-phosphorylations, while Roche will conduct clinical trials and assess the development of companion diagnostics (6/27) |
Gilead Sciences Inc. (Foster City, Calif.) |
Johnson & Johnson (New Brunswick, N.J.) |
ND |
License agreement to develop and commercialize a fixed-dose combination of Gilead's Phase III boosting agent cobicistat and Tibotec's Prezista for HIV |
Tibotec will be responsible for the formulation, manufacturing, registration, distribution and commercialization of the combination product worldwide (6/29) |
Hanwha Chemical Corp. (Seoul, South Korea) |
Merck and Co. Inc. (Whitehouse Station, N.J.) |
ND |
Development and commercialization agreement for a biosimilar form of Enbrel |
Merck made an undisclosed up-front payment to Hanwha, with possible additional milestone payments and tiered royalties on product sales (6/14) |
Heptares Therapeutics Ltd. (Welwyn Garden City, UK) |
AstraZeneca plc (London) |
$6.25 |
Four-year collaboration focused on discovery and development of new medicines for the treatment of central nervous system, metabolic and other diseases targeting G-protein coupled receptors |
Heptares will receive an up-front $6.25M cash payment plus committed research funding and potential milestone payments and royalties (6/1) |
Neuralstem Inc. (Rockville, Md.) |
Summit Pharmaceuticals International Corp. (Tokyo) |
ND |
Licensing agreement for its depression candidate, NSI-189 |
The agreement gives SPI the right to market development and licensing rights to the drug (6/8) |
PTC Therapeutics Inc. (South Plainfield, N.J.) |
AstraZeneca plc (London) |
ND |
Partnership for its Gene Expression Modulation by Small-molecules drug discovery platform; initially focused on oncology but could encompass up to eight targets across different therapeutic areas |
PTC will get an undisclosed amount of money from an up-front cash payment, committed research funding, milestone payments and royalties; PTC has an option to participate in the development of select product candidates (6/30) |
Sirnaomic Inc. (Gaithersburg, Md.) |
Guangdong Zhongsheng Pharmaceutical Co. Ltd. (Dongguan City, China) |
$9.75 |
Partnership to develop small interfering RNA for diabetic retinopathy and age-related macular degeneration |
The partnership will focus on clinical development and commercialization of STP601; Guangdong will commit $9.75M including up-front and milestone payments, and Sirnaomics also will be eligible for royalty sharing (6/24) |
Unigene Laboratories Inc. (Boonton, N.J.) |
China Pharmaceutical Group Ltd. (Hong Kong) |
$1.05 |
Deal to sell its 45% equity interest in Chinese joint venture Unigene Biotech-nology Co. Ltd. to China Pharmaceutical Group or one of its affiliates for $1.05M |
All technology licenses, sublicenses and other rights granted to the joint venture and China Pharmaceutical Group have been returned to Unigene; the venture was originally formed in June 2000 (6/14) |
Zealand Pharma A/S (Copenhagen, Denmark) |
Boehringer Ingelheim GmbH (Ingelheim, Germany) |
$537.3 |
Licensing agreement for exclusive global development and commercialization rights to its lead glucagon-GLP-1 dual agonist drug candidate, ZP2929 to treat Type II diabetes and obesity |
Zealand could earn as much as $537.3M in milestone and other payments, including $57.76M during the first two years (6/17) |
JULY |
Array BioPharma Inc. (Boulder, Colo.) |
Aslan Pharmaceuticals Pte Ltd. (Singapore) |
ND |
License agreement to develop Array's HER2/EGFR inhibitor, ARRY-543, currently starting Phase II development for solid tumors |
Aslan will fund and develop it through proof of concept, intitially targeting patients with gastric cancer through a program conducted in Asia; if proof of concept is achieved, Aslan will identify a global partner for Phase III development and commercialization (7/14) |
Astellas Pharma Inc. (Tokyo) |
Royalty Pharma (New York) |
$609 |
Astellas sold its IP assets relating to Prosidion's dipeptidyl peptidase IV inhibitors for Type II diabetes |
Royalty Pharma paid $609M and will now receive all royalty payments and milestones (7/5) |
Cambrex Corp. (East Rutherford, N.J.) |
Tillotts Pharma AG (Rheinfelden, Switzerland) |
ND |
Development and commercialization agreement for a mesalamine-based technology for use in the treatment of inflammatory bowel disease |
Tillotts acquired the worldwide exclusive rights to develop and commercialize products based on Cambrex' 5-ASA-based technology in exchange for undisclosed milestone payments, as well as royalties (7/7) |
Innate Pharma SA (Marseilles, France) |
Bristol-Myers Squibb Co. (Princeton, N.J.) |
$465 |
Collaboration for exclusive worldwide rights to IPH2102, as well as to related compounds designed to block KIR receptors, for all potential indications |
Innate will receive $35M up front, and BMS will fund work on IPH2102 and agreed to pay up to $430M in development and commercialization milestones, plus tiered, double-digit royalties on worldwide net sales (7/7) |
MediciNova Inc. (San Diego) |
Zhejiang Medicine Co. Ltd. (Hangzhou, China) |
ND |
Joint venture to develop and commercialize MediciNova's MN-221 in China |
The product is in development to treat acute exacerbations of asthma and chronic obstructive pulmonary disease (7/5) |
MingSight Pharmaceuticals (Taizhou, China) |
Shenzen Relin Medicin (Shenzen, China) |
ND |
Joint venture to develop and commercialize a therapy for diabetic eye disease in China |
The new venture, MingSight-Relin, will advance MS-533 (7/7) |
Pharmasset Inc. (Princeton, N.J.) |
Tibotec Pharmaceuticals Inc. (Raritan, N.J.) |
ND |
Collaboration to evaluate its nucleotide polymerase inhibitor PSI-7977 in combination with Tibotec's protease inhibitor TMC435 in a Phase II study in chronic hepatitis C virus |
Financial terms were not disclosed (7/7) |
Rib-X Pharmaceuticals Inc. (New Haven, Conn.) |
Sanofi SA (Paris) |
$763 |
Exclusive worldwide research collaboration and licensing option for antibiotics resulting from its RX-04 program to treat resistant Gram-positive and resistant Gram-negative pathogens |
Rib-X will receive $10M in an up-front payment and is eligible to receive up to an additional $9M in near-term research-based milestones, plus up to $86M in development and regulatory milestones, and more than $100M for commercial milestones, for a minimum of four target product profiles; total milestones could reach $744M (7/7) |
Vical Inc. (San Diego) |
Astellas Pharma Inc. (Tokyo) |
$130 |
License agreement for worldwide development and commercialization of Vical's TransVax vaccine for cytomegalovirus reactivation in hematopoietic stem cell transplant and solid organ transplant recipients |
Vical will get $25M up front and $10M more when design of a Phase III trial is completed; milestone payments of $95M could bring the total to $130M through launch, and Vical also could receive double-digit royalties (7/18) |
Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. * The total value represents the amount of disclosed money involving collaborations between biotechnology and pharmaceutical companies, including manufacturing, marketing and distribution agreements detailed in the following chart. ** Denotes the date the item ran in BioWorld International. |